

# Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278e)

## Filer's Information

---

Bertagnolli, Monica M

Director, NCI, Department of Health & Human Services

Date of Appointment: 10/03/2022

---

Other Federal Government Positions Held During the Preceding 12 Months:

None

---

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Bertagnolli, Monica M [electronically signed on 08/17/2022 by Bertagnolli, Monica M in Integrity.gov]

---

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Olesh, Stanley, Certifying Official [electronically signed on 11/28/2022 by Olesh, Stanley in Integrity.gov]

---

Other review conducted by

/s/ Olesh, Stanley, Ethics Official [electronically signed on 11/28/2022 by Olesh, Stanley in Integrity.gov]

---

U.S. Office of Government Ethics Certification

---

Data Revised 11/28/2022

Data Revised 10/05/2022

Data Revised 10/03/2022

Data Revised 08/31/2022

Data Revised 08/26/2022

Data Revised 08/25/2022

Data Revised 08/20/2022

Data Revised 08/19/2022

---

Comments of Reviewing Officials (public annotations):

PART	#	REFERENCE	COMMENT
N/A	N/A	General	(10/05/2022, Olesh, Stanley): 8/19/22 - I/R --SO
N/A	N/A	General	(10/05/2022, Olesh, Stanley): 9/15/22 - rec'd signed EA -- SO
N/A	N/A	General	(11/28/2022, Olesh, Stanley): 11/27 -- obtained compliance documentation re: prior employment/activities -- SO

---

## 1. Filer's Positions Held Outside United States Government

#	ORGANIZATION NAME	CITY, STATE	ORGANIZATION TYPE	POSITION HELD	FROM	TO
1	Dana-Farber Cancer Inst./Brigham & Women's Hospital	Boston, Massachusetts	Non-Profit	physician	10/1999	9/2022
2	American Cancer Society	Atlanta, Georgia	Non-Profit	Board of Directors	7/2021	8/2022
3	American Society of Clinical Oncology	Alexandria, Virginia	Non-Profit	Board of Directors	6/2017	6/2021
4	MITRE Corporation	Bedford, Massachusetts	Non-Profit	Consultant	1/2022	8/2022
5	Prevent Cancer Foundation	Alexandria, Virginia	Non-Profit	Board of Directors	1/2022	8/2022
6	Natera, Inc.	San Carlos, California	Corporation	Board of Directors	7/2020	8/2022
7	Leap Therapeutics	Cambridge, Massachusetts	Corporation	Board of Directors	3/2019	8/2022
8	Oncoclinicas Do Brasil Servicos Medicos	Sao Paulo, Outside U.S.	Corporation	Board of Directors	7/2021	8/2022
9	Alliance for Clinical Trials in Oncology	Chicago, Illinois	Non-Profit	President	6/2008	9/2022
10	White Acorn Ranch	Newton, Massachusetts	Corporation	Secretary	1/1994	Present
11	Bertagnolli and Dannenberg, LLC	Newton, Massachusetts	Corporation	Secretary	6/1994	Present
12	MD Anderson Cancer Center	Houston, Texas	Non-Profit	advisory board	1/2020	8/2022
13	Damon Runyon Cancer Foundation	New York, New York	Non-Profit	advisory board	1/2021	8/2022
14	BioAscend	Chicago, Illinois	Corporation	meeting faculty	1/2021	1/2022

#	ORGANIZATION NAME		CITY, STATE	ORGANIZATION TYPE	POSITION HELD	FROM	TO
15	City of Hope		Duarte, California	Non-Profit	meeting faculty	2/2021	2/2022
16	Duke University		Durham, North Carolina	Non-Profit	visiting faculty	1/2021	8/2022
17	Fred Hutchinson Cancer Research Center		Seattle, Washington	Non-Profit	visiting faculty	1/2021	8/2022
18	Northwell Health		New Hyde Park, New York	Non-Profit	visiting faculty	1/2021	8/2022
19	Mayo Clinic Foundation		Rochester, Minnesota	Non-Profit	visiting faculty	1/2020	1/2021
20	BJC Healthcare		St Louis, Missouri	Non-Profit	visiting faculty	1/2020	1/2021
21	Alliance for Clinical Trials in Oncology Foundation	See Endnote	Chicago, Illinois	Non-Profit	President	1/2010	8/2022
22	Alliance Foundation Trials, LLC	See Endnote	Boston, Massachusetts	LLC	President	1/2013	8/2022
23	Alliance Data Innovation Lab, LLC	See Endnote	Boston, Massachusetts	LLC	President	1/2017	8/2022
24	Alliance NCTN Foundation		Chicago, Illinois	Non-Profit	President	1/2019	8/2022
25	Harvard Medical School		Cambridge, Massachusetts	University/College	Faculty (Professor of Surgery)	1/2008	8/2022
26	Coalition of Cancer Cooperative Groups		Philadelphia, Pennsylvania	Non-Profit	Vice President	1/2014	8/2022
27	Association for Clinical Oncology		Alexandria, Virginia	Professional Association	Chair, Board of Directors	1/2020	6/2021
28	Syntalogic Pharmaceuticals		New York, New York	Corporation	Consultant	9/2018	10/2020

#	ORGANIZATION NAME	CITY, STATE	ORGANIZATION TYPE	POSITION HELD	FROM	TO
29	VREX Therapeutics, Inc	Cambridge, Massachusetts	Corporation	consultant	5/2020	1/2021
30	University of Utah Huntsman Cancer Institute	Salt Lake City, Utah	Non-Profit	Member, External Advisory Board	3/2021	8/2022
31	V Foundation	Cary, North Carolina	Non-Profit	Advisory Committee	2/2022	8/2022
32	Vivli Center for Global Clinical Research Data	Cambridge, Massachusetts	Non-Profit	Member, External Advisory Committee	3/2017	8/2022
33	American College of Surgeons	Chicago, Illinois	Non-Profit	Fellow	12/2020	8/2022

## 2. Filer's Employment Assets & Income and Retirement Accounts

#	DESCRIPTION	EIF	VALUE	INCOME TYPE	INCOME AMOUNT
1	MITRE Corporation	N/A		Consulting Fees	\$12,500
2	Dana Farber Cancer Inst./Brigham & Women's Hospital	N/A		Salary	\$1,609,198
3	Natera, Inc., stock options (value not readily ascertainable): 1306 vested call options; strike price \$94.14 expires 5/27/31 2614 unvested call options; strike price \$94.14 expires 5/27/31	N/A			None (or less than \$201)
4	Alliance for Clinical Trials in Oncology	N/A		reimbursement for on site parking	\$10,240

#	DESCRIPTION	EIF	VALUE	INCOME TYPE	INCOME AMOUNT
5	Oncoclinicas Do Brasil Servicos Medicos, stock options (value not readily ascertainable): 200,000 unvested stock options; strike price 6.8 Brazilian Reis; expires 5/18/32	N/A			None (or less than \$201)
6	Oncoclinicas Do Brasil Servicos Medicos	N/A		Director Fees	\$50,025
7	Leap Therapeutics, stock options (value not readily ascertainable): vested options to buy: 32,400 shares; strike price \$1.58; expire 9/8/31; 27,500 shares; strike price \$1.94; expire 1/31/32 unvested options to buy: 48,750 shares strike price \$1.58; vesting date 9/7/22-9/7/24; expire 9/8/31 27,500 shares strike price \$1.94; vesting date 10/1/22-1/1/23; expire 1/31/32	N/A			None (or less than \$201)
8	Leap Therapeutics	N/A		Director Fees	\$40,250
9	Brigham & Women's Hospital retirement plan	No			
9.1	Brigham & Women's Hospital - 403(b) -- 100% in Vanguard Target Retirement 2025 (VTTVX)	Yes	\$1,000,001 - \$5,000,000		None (or less than \$201)
9.2	Mass General Brigham - 403(b) -- 100% in Vanguard Target Retirement 2025 (VTTVX)	Yes	\$500,001 - \$1,000,000		None (or less than \$201)
9.3	Mass General Brigham 457(b) - 100% in Vanguard Target Retirement 2025 (VTTVX)	Yes	\$100,001 - \$250,000		None (or less than \$201)
9.4	Mass General Brigham 401(A) - 100% in Vanguard Target Retirement 2025 (VTTVX)	Yes	\$15,001 - \$50,000		None (or less than \$201)
10	Weill Cornell Medical College	No			
10.1	TIAA Traditional Annuity-Supplemental Retirement AnnuityCREF	Yes	\$1,001 - \$15,000		None (or less than \$201)
10.2	Vanguard Federal Money Market Fund (VMFXX)	Yes	\$15,001 - \$50,000		None (or less than \$201)

#	DESCRIPTION		EIF	VALUE	INCOME TYPE	INCOME AMOUNT
11	White Acorn Ranch (Cattle ranch - family business)	See Endnote	N/A	\$1,000,001 - \$5,000,000		None (or less than \$201)
12	Natera, Inc.		N/A	\$50,001 - \$100,000		None (or less than \$201)
13	Natera, Inc.	See Endnote	N/A		Director Fees	\$39,582
14	MD Anderson Cancer Center		N/A		Consulting Fees	\$6,000
15	Damon Runyon Cancer Foundation		N/A		Consulting Fees	\$1,000
16	City of Hope		N/A		honorarium	\$1,000
17	Duke University		N/A		honorarium	\$600
18	Fred Hutchinson Cancer Research Center		N/A		honorarium	\$1,000
19	Northwell Health		N/A		honorarium	\$1,000
20	US patent No 13/922,943: 15-PGDH in Colon Cancer		N/A	None (or less than \$1,001)		None (or less than \$201)
21	US Patent No 9061004 B2: 15-PGDH in Colon Cancer		N/A	None (or less than \$1,001)		None (or less than \$201)
22	WIPO PCTWO 2020/118295 A1: Humanized and Affinity-Matured Anti-CEACAM1 Antibodies	See Endnote	N/A	None (or less than \$1,001)		None (or less than \$201)
23	BioAscend		N/A		honorarium	\$1,500
24	Mayo Clinic Foundation		N/A		honorarium	\$1,000
25	BJC Healthcare		N/A		honoraria	\$2,700
26	Bertagnolli & Dannenberg LLC	See Endnote	N/A	\$1,000,001 - \$5,000,000		None (or less than \$201)

### 3. Filer's Employment Agreements and Arrangements

#	EMPLOYER OR PARTY	CITY, STATE	STATUS AND TERMS	DATE
1	Natera, Inc.	San Carlos, California	exercise value currently below strike prices therefore will either forfeit or transfer vested options; will forfeit unvested options	5/2021
2	Oncoclinicas Do Brasil Servicos Medicos	Sao Paulo, Outside U.S.	all unvested options will be forfeited	5/2022
3	Leap Therapeutics	Cambridge, Massachusetts	will transfer vested options; will forfeit unvested options	9/2021
4	Brigham & Women's Hospital	Boston, Massachusetts	I will continue to participate in this defined contribution plan, and the plan sponsor will not continue to make contributions.	10/1999
5	Weill Cornell Medical College	New York, New York	I will not participate in this defined contribution plan after my separation.	7/1994

### 4. Filer's Sources of Compensation Exceeding \$5,000 in a Year

#	SOURCE NAME	CITY, STATE	BRIEF DESCRIPTION OF DUTIES
1	MITRE Corporation	Bedford, Massachusetts	Consultant
2	DFCI/BWH	Boston, Massachusetts	Physician
3	Alliance for Clinical Trials in Oncology	Chicago, Illinois	President
4	Leap Therapeutics	Cambridge, Massachusetts	Board of Directors
5	Oncoclinicas Do Brasil Servicos Medicos	Sao Paulo, Outside U.S.	Board of Directors
6	Natera, Inc.	San Carlos, California	Board of Directors



#	SOURCE NAME	CITY, STATE	BRIEF DESCRIPTION OF DUTIES
7	MD Anderson Cancer Center	Houston, Texas	Consultant

## 5. Spouse's Employment Assets & Income and Retirement Accounts

#	DESCRIPTION	EIF	VALUE	INCOME TYPE	INCOME AMOUNT
1	Jewish Family & Children's Services See Endnote	N/A	\$1,001 - \$15,000	\$560 per month as caregiver support for disabled son	
2	Geode Capital 401K held at Fidelity -- 100% in Fidelity Government Money Mkt Fund (SPAXX)	Yes	\$250,001 - \$500,000		None (or less than \$201)
3	BNP PARIBAS retirement plan -- 100% in Fidelity Treasury Only Money Mkt Fund (FDLXX)	Yes	\$15,001 - \$50,000		None (or less than \$201)
4	Self Employment IRA (SEP-IRA) - 100% cash account	N/A	\$100,001 - \$250,000		None (or less than \$201)

## 6. Other Assets and Income

#	DESCRIPTION	EIF	VALUE	INCOME TYPE	INCOME AMOUNT
1	Capital One Checking Account See Endnote	N/A	\$100,001 - \$250,000		None (or less than \$201)
2	Capital One Money Market Savings See Endnote	N/A	\$15,001 - \$50,000		None (or less than \$201)
3	JP Morgan Chase checking account See Endnote	N/A	\$500,001 - \$1,000,000		None (or less than \$201)

#	DESCRIPTION		EIF	VALUE	INCOME TYPE	INCOME AMOUNT
4	JP Morgan Chase savings account	See Endnote	N/A	\$1,001 - \$15,000		None (or less than \$201)
5	Brookline Bank Money Market Account	See Endnote	N/A	\$500,001 - \$1,000,000		None (or less than \$201)
6	Brookline Bank Checking Account	See Endnote	N/A	\$50,001 - \$100,000		None (or less than \$201)
7	Brokerage Account - Fidelity		No			None (or less than \$201)
7.1	Fidelity FCASH cash sweep acct		N/A	\$100,001 - \$250,000		None (or less than \$201)
7.2	Ameriprise Financial, Inc. (AMP)		N/A	\$1,001 - \$15,000		None (or less than \$201)
8	Fidelity U Fund - MA 529 Plan (100% in College Portfolio)		Yes	\$15,001 - \$50,000		None (or less than \$201)
9	MetLife Whole Life policy	See Endnote	N/A	\$1,001 - \$15,000		None (or less than \$201)
10	Selkirk Pharma, preferred stock series 1 57,656 shares; series 2 17,095 shares (value not readily ascertainable)	See Endnote	N/A			None (or less than \$201)
11	Finitive Holdings, Inc., convertible note (value not readily ascertainable)	See Endnote	N/A			None (or less than \$201)

## 7. Transactions

(N/A) - Not required for this type of report

## 8. Liabilities

None

---

## 9. Gifts and Travel Reimbursements

(N/A) - Not required for this type of report

---

### Endnotes

PART	#	ENDNOTE
1.	21	There is a single board of directors and President, with consolidated financial management, for the Alliance for Clinical Trials in Oncology Foundation; Alliance Foundation Trials, LLC; and Alliance Data Innovation Lab, LLC
1.	22	There is a single board of directors and President, with consolidated financial management, for the Alliance for Clinical Trials in Oncology Foundation; Alliance Foundation Trials, LLC; and Alliance Data Innovation Lab, LLC
1.	23	There is a single board of directors and President, with consolidated financial management, for the Alliance for Clinical Trials in Oncology Foundation; Alliance Foundation Trials, LLC; and Alliance Data Innovation Lab, LLC
2.	11	This entity owns the land of the family cattle ranch, while Bertagnolli & Dannenberg LLC owns the cattle and some farmland
2.	13	cash compensation -- some compensation was in stock, included in Natera stock entry.
2.	22	Antibody that is under development as an immunotherapy for cancer
2.	26	This entity owns the cattle and some farmland in the family cattle ranch, while White Acorn Ranch owns the ranch land
5.	1	A MassHealth/Medicaid Adult Family Caregiver (AFC) program
6.	1	checking account
6.	2	Savings account

PART	#	ENDNOTE
6.	3	checking account
6.	4	savings account
6.	5	savings account
6.	6	checking account
6.	9	\$770,000 life insurance coverage; estimated value \$3500
6.	10	seed investor in the new company
6.	11	seed investor in the new company

# Summary of Contents

## 1. Filer's Positions Held Outside United States Government

Part 1 discloses positions that the filer held at any time during the reporting period (excluding positions with the United States Government). Positions are reportable even if the filer did not receive compensation.

This section does not include the following: (1) positions with religious, social, fraternal, or political organizations; (2) positions solely of an honorary nature; (3) positions held as part of the filer's official duties with the United States Government; (4) mere membership in an organization; and (5) passive investment interests as a limited partner or non-managing member of a limited liability company.

## 2. Filer's Employment Assets & Income and Retirement Accounts

Part 2 discloses the following:

- Sources of earned and other non-investment income of the filer totaling more than \$200 during the reporting period (e.g., salary, fees, partnership share, honoraria, scholarships, and prizes)
- Assets related to the filer's business, employment, or other income-generating activities (1) that ended the reporting period with a value greater than \$1,000 or (2) from which more than \$200 in income was received during the reporting period (e.g., equity in business or partnership, stock options, retirement plans/accounts and their underlying holdings as appropriate, deferred compensation, and intellectual property, such as book deals and patents)

This section does not include assets or income from United States Government employment or assets that were acquired separately from the filer's business, employment, or other income-generating activities (e.g., assets purchased through a brokerage account). Note: The type of income is not required if the amount of income is \$0 - \$200 or if the asset qualifies as an excepted investment fund (EIF).

## 3. Filer's Employment Agreements and Arrangements

Part 3 discloses agreements or arrangements that the filer had during the reporting period with an employer or former employer (except the United States Government), such as the following:

- Future employment
- Leave of absence
- Continuing payments from an employer, including severance and payments not yet received for previous work (excluding ordinary salary from a current employer)
- Continuing participation in an employee welfare, retirement, or other benefit plan, such as pensions or a deferred compensation plan
- Retention or disposition of employer-awarded equity, sharing in profits or carried interests (e.g., vested and unvested stock options, restricted stock, future share of a company's profits, etc.)

#### 4. Filer's Sources of Compensation Exceeding \$5,000 in a Year

Part 4 discloses sources (except the United States Government) that paid more than \$5,000 in a calendar year for the filer's services during any year of the reporting period.

The filer discloses payments both from employers and from any clients to whom the filer personally provided services. The filer discloses a source even if the source made its payment to the filer's employer and not to the filer. The filer does not disclose a client's payment to the filer's employer if the filer did not provide the services for which the client is paying.

#### 5. Spouse's Employment Assets & Income and Retirement Accounts

Part 5 discloses the following:

- Sources of earned income (excluding honoraria) for the filer's spouse totaling more than \$1,000 during the reporting period (e.g., salary, consulting fees, and partnership share)
- Sources of honoraria for the filer's spouse greater than \$200 during the reporting period
- Assets related to the filer's spouse's employment, business activities, other income-generating activities (1) that ended the reporting period with a value greater than \$1,000 or (2) from which more than \$200 in income was received during the reporting period (e.g., equity in business or partnership, stock options, retirement plans/accounts and their underlying holdings as appropriate, deferred compensation, and intellectual property, such as book deals and patents)

This section does not include assets or income from United States Government employment or assets that were acquired separately from the filer's spouse's business, employment, or other income-generating activities (e.g., assets purchased through a brokerage account). Note: The type of income is not required if the amount of income is \$0 - \$200 or if the asset qualifies as an excepted investment fund (EIF). Amounts of income are not required for a spouse's earned income (excluding honoraria).

#### 6. Other Assets and Income

Part 6 discloses each asset, not already reported, (1) that ended the reporting period with a value greater than \$1,000 or (2) from which more than \$200 in investment income was received during the reporting period. For purposes of the value and income thresholds, the filer aggregates the filer's interests with those of the filer's spouse and dependent children.

This section does not include the following types of assets: (1) a personal residence (unless it was rented out during the reporting period); (2) income or retirement benefits associated with United States Government employment (e.g., Thrift Savings Plan); and (3) cash accounts (e.g., checking, savings, money market accounts) at a single financial institution with a value of \$5,000 or less (unless more than \$200 in income was received). Additional exceptions apply. Note: The type of income is not required if the amount of income is \$0 - \$200 or if the asset qualifies as an excepted investment fund (EIF).

## 7. Transactions

Part 7 discloses purchases, sales, or exchanges of real property or securities in excess of \$1,000 made on behalf of the filer, the filer's spouse or dependent child during the reporting period.

This section does not include transactions that concern the following: (1) a personal residence, unless rented out; (2) cash accounts (e.g., checking, savings, CDs, money market accounts) and money market mutual funds; (3) Treasury bills, bonds, and notes; and (4) holdings within a federal Thrift Savings Plan account. Additional exceptions apply.

## 8. Liabilities

Part 8 discloses liabilities over \$10,000 that the filer, the filer's spouse or dependent child owed at any time during the reporting period.

This section does not include the following types of liabilities: (1) mortgages on a personal residence, unless rented out (limitations apply for PAS filers); (2) loans secured by a personal motor vehicle, household furniture, or appliances, unless the loan exceeds the item's purchase price; and (3) revolving charge accounts, such as credit card balances, if the outstanding liability did not exceed \$10,000 at the end of the reporting period. Additional exceptions apply.

## 9. Gifts and Travel Reimbursements

This section discloses:

- Gifts totaling more than \$415 that the filer, the filer's spouse, and dependent children received from any one source during the reporting period.
- Travel reimbursements totaling more than \$415 that the filer, the filer's spouse, and dependent children received from any one source during the reporting period.

For purposes of this section, the filer need not aggregate any gift or travel reimbursement with a value of \$166 or less. Regardless of the value, this section does not include the following items: (1) anything received from relatives; (2) anything received from the United States Government or from the District of Columbia, state, or local governments; (3) bequests and other forms of inheritance; (4) gifts and travel reimbursements given to the filer's agency in connection with the filer's official travel; (5) gifts of hospitality (food, lodging, entertainment) at the donor's residence or personal premises; and (6) anything received by the filer's spouse or dependent children totally independent of their relationship to the filer. Additional exceptions apply.

## Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13770 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.

## Public Burden Information

This collection of information is estimated to take an average of ten hours per response, including time for reviewing the instructions, gathering the data needed, and completing the form. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Program Counsel, U.S. Office of Government Ethics (OGE), Suite 500, 1201 New York Avenue, N.W., Washington, DC 20005-3917.

Pursuant to the Paperwork Reduction Act, as amended, an agency may not conduct or sponsor, and no person is required to respond to, a collection of information unless it displays a currently valid OMB control number (that number, 3209-0001, is displayed here and at the top of the first page of this OGE Form 278e).

---